Abstract
Background:
The U.S. Food and Drug Administration has proposed administering annual SARS-CoV-2 vaccines.
Objective:
To evaluate the effectiveness of an annual SARS-CoV-2 vaccination campaign, quantify the health and economic benefits of a second dose provided to children younger than 2 years and adults aged 50 years or older, and optimize the timing of a second dose.
Design:
An age-structured dynamic transmission model.
Setting:
United States.
Participants:
A synthetic population reflecting demographics and contact patterns in the United States.
Intervention:
Vaccination against SARS-CoV-2 with age-specific uptake similar to that of influenza vaccination.
Measurements:
Incidence, hospitalizations, deaths, and direct health care cost.